Premium functions are now FREE OF CHARGE due to the modification of the investment data Data developments may cause some parts work incorrectly Incorrect sections - Financial statements, Earnings upcoming dates and calendars Please take our apologise. It will be fixed soon

VTRS - Viatris Inc


IEX Last Trade
12.095
0.205   1.695%

Share volume: 6,717,046
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$11.89
0.21
1.72%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
23%
Profitability 6%
Dept financing 43%
Liquidity 55%
Performance 27%
Company vs Stock growth
vs
Performance
5 Days
2.72%
1 Month
0.62%
3 Months
16.46%
6 Months
2.54%
1 Year
17.55%
2 Year
41.33%
Key data
Stock price
$12.10
P/E Ratio 
-22.30
DAY RANGE
N/A - N/A
EPS 
-$0.54
52 WEEK RANGE
$8.17 - $13.05
52 WEEK CHANGE
$0.20
MARKET CAP 
14.418 B
YIELD 
3.89%
SHARES OUTSTANDING 
1.194 B
DIVIDEND
$0.12
EX-DIVIDEND DATE
08/23/2024
NEXT EARNINGS DATE
11/05/2024
BETA 
0.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,511,924
AVERAGE 30 VOLUME 
$7,837,639
Company detail
CEO: Michael Goettler
Region: US
Website: mylan.com
Employees: 12,348
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.

Recent news